Lung cancer resistant to EGFR pills was slowed longer by a two-target drug than by chemo
In a phase 3 trial published Oct. 26, 2026, in The Lancet, people with EGFR lung cancer that had grown on third-generation EGFR pills went a median 11.1 months without progression on…